Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is tenosynovial giant cell tumor?
Tenosynovial giant cell tumor (TGCT) is a benign — non-cancerous — but locally aggressive growth that arises from the synovium, the lining of joints, tendon sheaths, and the fluid-filled sacs (bursae) around joints. It is sometimes called pigmented villonodular synovitis (PVNS) when it affects a whole joint. It is driven by overproduction of a signaling protein called CSF1, which recruits inflammatory cells that build up into a mass. There are two main patterns: a small, localized nodule (most often on a finger, as 'giant cell tumor of the tendon sheath') and a diffuse form that involves a larger joint such as the knee or hip. Although it does not spread to other organs, the diffuse type can grow, cause swelling, pain, stiffness, and locking, and can erode the cartilage and bone of a joint over time. Treatment aims to remove the disease and protect the joint. When surgery cannot fully control diffuse disease, targeted medicines that block CSF1 signaling — and, in selected cases, radiation — are used.
The main types
Doctors group tenosynovial giant cell tumor by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Localized type | A discrete, well-defined nodule, most commonly on the fingers (giant cell tumor of the tendon sheath); usually cured by removing the nodule. |
| Diffuse type (PVNS) | Involves much of a joint lining, most often the knee or hip; more likely to recur after surgery and to damage the joint, so it often needs additional treatment. |
| Malignant tenosynovial giant cell tumor (very rare) | An extremely rare cancerous form that can spread; treated like a soft-tissue sarcoma at an expert center. |
Staging, in plain terms
Because TGCT is benign, it is not given a cancer stage. What matters clinically is whether it is the localized or diffuse type, which joint is affected, how much joint damage has occurred, and whether it has recurred. The very rare malignant form is staged like a soft-tissue sarcoma.
| No formal cancer staging (benign tumor) | What it generally means |
|---|---|
| Localized disease | A single, well-defined nodule; generally cured by complete surgical removal with a low chance of return. |
| Diffuse disease | Widespread involvement of a joint lining; harder to remove completely, more likely to recur, and more likely to need targeted medicine or radiation. |
| Recurrent or joint-damaging disease | Disease that has come back or worn down the joint; managed with repeat or more extensive surgery, targeted therapy, and sometimes joint reconstruction. |
The standard of care
Tenosynovial Giant Cell Tumor is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (the main treatment)
Removing the tumor — by open surgery or arthroscopy, often called synovectomy for the diffuse type — is the cornerstone. Localized disease is usually cured; diffuse disease has a higher chance of returning.
Targeted medicine (CSF1R inhibitors)
For diffuse, recurrent, or hard-to-remove disease where surgery would cause serious harm, oral CSF1R-inhibitor drugs — pexidartinib and the newer vimseltinib — shrink tumors and improve symptoms; vimseltinib (approved in 2025) offers a more favorable liver-safety profile.
Joint preservation and rehabilitation
Physical therapy and, when a joint is badly damaged, reconstructive surgery (including joint replacement) help restore function.
Long-term follow-up
Because the diffuse type can recur, periodic examination and MRI help detect and address any return early.
How radiation treatment works
Radiation damages the DNA inside the overgrown synovial cells so they can no longer divide, while normal tissue repairs itself more effectively. In tenosynovial giant cell tumor, surgery and targeted medicines lead treatment, and radiation has a selective role — mainly for diffuse disease that surgery cannot fully clear — to lower the chance of recurrence. It can be delivered from outside the body in short, painless sessions, or, at some centers, by injecting a radioactive material into the joint to treat the lining from within. External radiation leaves no radioactivity in your body.
The main ways radiation is delivered for tenosynovial giant cell tumor:
Radiation after incomplete surgery
For diffuse disease that cannot be completely removed, moderate-dose external radiation to the joint can reduce the chance of recurrence by treating the microscopic disease left behind.
Radiosynovectomy (injected radiation)
In selected diffuse cases, a radioactive material is injected into the joint to treat the lining from within; this is used at some centers as an alternative or addition to external radiation.
Palliative / function-preserving radiation
Radiation can help control persistent or recurrent disease in a joint that is difficult to operate on, aiming to relieve symptoms and protect joint function.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Vimseltinib approved for TGCT (2025): Based on the phase 3 MOTION trial, the CSF1R inhibitor vimseltinib was approved in 2025 for symptomatic TGCT not amenable to surgery, with about 40% of tumors responding and an improved liver-safety profile compared with pexidartinib.[1]
MOTION trial and 2025 vimseltinib approval
Pexidartinib as the first targeted option: Pexidartinib, the first CSF1R inhibitor approved for severe, hard-to-operate TGCT, demonstrated meaningful tumor responses, establishing targeted CSF1 blockade as an effective non-surgical approach.[2]
ENLIVEN trial and pexidartinib label
Surgery remains first-line, with radiation selective: Outcome studies confirm surgery as the primary treatment, with radiation reserved for diffuse disease that cannot be fully removed, balanced against the long-term risks of irradiating a joint.[3]
Orthopedic oncology TGCT management reviews (2021–2025)
Common questions
Is this cancer? No. Tenosynovial giant cell tumor is benign — it does not spread to other organs. However, the diffuse type can grow within a joint, cause pain and stiffness, damage cartilage and bone, and come back after surgery, so it is treated seriously. A malignant form exists but is extremely rare.
Why might I need a pill instead of (or in addition to) surgery? When the tumor diffusely involves a joint and surgery alone can't remove it all — or would cause serious functional loss — targeted CSF1R-inhibitor medicines like vimseltinib or pexidartinib can shrink the tumor and relieve symptoms. They are used for symptomatic disease that isn't suitable for surgery.
When is radiation used? Radiation is selective. It is mainly considered for diffuse disease that surgery cannot completely remove, to lower the chance of recurrence. Your team weighs that benefit against the long-term effects of radiating a joint, and will discuss whether external radiation or an injected (radiosynovectomy) approach fits your situation.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.